3 active not recruiting, 1 recruiting, 1 withdrawn. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Primary Peritoneal Clear Cell Adenocarcinoma: new trials by email Literature Review of Recurrent Primary Peritoneal Clear Cell Adenocarcinoma trials Research Report on Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-26 |
Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Fallopian Tube Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Ovarian Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3)
Disulfides (4) · Immunoglobulin G (4) · Bevacizumab (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Doxorubicin (2) · Paclitaxel (2) · Taxes (2) · liposomal doxorubicin (2) · pembrolizumab (2) · ASTX-660 (1) · Biopsy (1) · Blood Component Removal (1) · Contrast Media (1) · Topotecan (1)
National Cancer Institute (NCI) (3) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (4) · Puerto Rico (2)
Emese Zsiros (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Matthew S. Block, MD, PhD (1) · Roisin E O'Cearbhaill (1)
U10CA180868 (3), R01CA276313 (1)